CJC-1295 Peptide: Research Overview, Purity Data and Where to Buy

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), built from the first 29 amino acids of human GHRH with four amino acid substitutions and, in one variant, an albumin-binding linker. Developed in the early 2000s, it is studied in laboratory settings for its effects on growth hormone and IGF-1 signaling.

What CJC-1295 Is and Where It Came From

Native human GHRH is a 44-amino-acid hypothalamic peptide. Decades of endocrine work established that its biological activity lives almost entirely in the first 29 residues — the fragment known as GRF(1-29), or sermorelin. That fragment has an obvious practical problem for researchers: it degrades quickly, chiefly through cleavage by dipeptidyl peptidase-4 (DPP-4) at the N-terminus, giving it a plasma half-life measured in minutes.

CJC-1295 was designed by the Canadian biotechnology company ConjuChem in the early 2000s as an answer to that problem. The molecule takes the GRF(1-29) backbone and introduces four substitutions — commonly described as D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27 — that blunt enzymatic degradation and improve conformational stability. The version that carries ConjuChem's Drug Affinity Complex (DAC) adds a lysine linker bearing a maleimidopropionyl group, which forms a covalent bond with circulating serum albumin. Because albumin itself has a long residence time in plasma, the conjugated peptide is shielded from renal clearance and proteolysis.

This design split produced the two entities researchers encounter today, and conflating them is the single most common source of confusion in the literature and in commercial listings.

Strictly speaking, "CJC-1295 no DAC" is a marketplace name rather than a literature name; the published record generally reserves CJC-1295 for the DAC-conjugated compound and refers to the unconjugated peptide as modified GRF 1-29 or CJC-1295 without DAC. Researchers reading older papers should assume the DAC form unless stated otherwise.

Reported Mechanism of Action

The proposed mechanism is straightforward receptor pharmacology. CJC-1295 binds the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed densely on somatotroph cells of the anterior pituitary. Receptor engagement activates adenylate cyclase, raises intracellular cAMP, and promotes both the release of stored growth hormone and the transcription of new GH. Downstream, GH acts on hepatic and peripheral tissue to drive production of insulin-like growth factor 1 (IGF-1), which mediates much of the anabolic signaling attributed to the axis and also provides negative feedback at the hypothalamus and pituitary.

Two features of this mechanism are worth emphasizing because they shape how the compound is studied. First, CJC-1295 acts upstream of the pituitary rather than replacing GH directly, so its output remains subject to somatostatin tone and IGF-1 feedback — a ceiling that exogenous GH bypasses. Second, and counterintuitively, prolonged receptor occupancy does not appear to flatten GH release into a continuous infusion-like pattern. One of the 2006 clinical reports specifically examined this and found that pulsatile GH secretion persisted during continuous stimulation by CJC-1295, with the peptide raising both trough and pulse amplitude rather than abolishing the underlying rhythm. That observation is central to why the compound remains of interest to endocrine researchers: physiological pulsatility appears to be preserved.

What the Published Research Examines

Endocrine pharmacology in healthy adults: the core human dataset comes from early clinical work published in 2006 in The Journal of Clinical Endocrinology and Metabolism, which reported several-fold increases in circulating growth hormone in healthy adults, alongside elevations in IGF-1 that were sustained for days rather than hours. Those studies are the origin of the widely cited multi-day half-life figures. They were, however, small, short, and conducted in normal volunteers — evidence remains preliminary and should not be read as an efficacy record for any clinical application.

Downstream biomarker changes

A 2009 paper in Growth Hormone & IGF Research extended this by profiling serum proteins in normal adult subjects following activation of the GH/IGF-1 axis by CJC-1295, reporting measurable shifts in the circulating protein profile. This line of work is useful less as a clinical endpoint than as a demonstration that upstream GHRH-receptor stimulation produces detectable, systemic downstream signatures — a point relevant to both biomarker research and doping control.

Preclinical models

In rodent models, once-daily administration of CJC-1295 was reported to normalize growth in the GHRH knockout mouse, a model with an intact pituitary but absent endogenous GHRH signaling. That result supports the receptor-level mechanism described above, though extrapolating growth normalization in a genetically GHRH-deficient animal to any effect in a hormonally intact organism is not supportable on the current evidence.

Analytical chemistry and anti-doping detection

A substantial share of the modern literature is methodological rather than physiological. Papers from 2019 in Drug Testing and Analysis describe an LC-MS/MS confirmation method and an immuno-PCR screening assay for detecting CJC-1295 and related GHRH analogs in equine plasma. An earlier 2010 report in the same journal documented the identification of CJC-1295 in an unknown pharmaceutical preparation — an early signal that the compound had moved outside controlled settings. For laboratories, these papers are valuable as identity-confirmation references and as a reminder that the compound is a monitored substance in sport.

Sociological and behavioral research

A 2016 netnographic study in Substance Use & Misuse analyzed online communities discussing female use of CJC-1295, documenting how information about the peptide circulates, is negotiated, and diverges from the published evidence base. It is a study of discourse, not of pharmacology, but it is one of the more honest windows into the gap between what the literature actually establishes and what is claimed informally.

Areas commonly discussed but thinly evidenced

Topics such as body composition change, sleep architecture, recovery, connective tissue, and cognition appear frequently in secondary discussion of CJC-1295. Controlled human data specific to this compound in those domains is sparse to absent. Where inferences are drawn, they typically come from the broader GH/IGF-1 literature rather than from CJC-1295 trials — a distinction worth preserving in any literature review.

Laboratory Handling: Reconstitution and Storage

CJC-1295 is supplied as a lyophilized (freeze-dried) white powder under vacuum. In that state it is comparatively stable and is generally stored cold and protected from light; long-term storage in a freezer is standard practice for reference material, with refrigeration typical for material in active use. Repeated freeze-thaw cycling is avoided because it is a known driver of peptide aggregation and loss of measurable purity.

Reconstitution is normally performed with bacteriostatic or sterile water introduced slowly against the inner wall of the vial rather than directly onto the peptide cake. Peptides of this class are surface-active and shear-sensitive; vigorous shaking can denature material and produce visible haze or particulate. Gentle swirling until the cake dissolves is the standard approach, followed by visual inspection — a properly reconstituted solution should be clear and free of visible particulate.

Once in solution, stability drops considerably. Reconstituted material is refrigerated, kept out of light, and treated as having a limited working window; the DAC and no-DAC variants are not assumed to behave identically in solution. Laboratories that need extended solution stability generally aliquot to avoid repeated warming of a single vial. Detailed protocols, calculators, and troubleshooting for cloudy or temperature-exposed material are covered in dedicated articles across this hub.

Regulatory and Research-Use Status

CJC-1295 is not an approved drug. It has not been authorized by the FDA for any of the applications discussed on this page, it has no approved indication, and it is not a compounded or prescribable pharmaceutical in the United States. Clinical development by its originator did not carry it to market approval. It is supplied here as a research chemical for laboratory research only — for in vitro work and controlled experimental use by qualified personnel — and it is not intended for human or veterinary use, diagnostic use, or consumption in any form.

Separately, GHRH analogs including CJC-1295 fall within the World Anti-Doping Agency's prohibited classes covering peptide hormones and growth factors, and they are prohibited at all times in sport. The equine detection methods described above exist precisely because the compound is also monitored in animal athletics. Researchers should also be aware that the legal framing of purchase and possession varies by jurisdiction and that intent of use is the operative distinction in most regulatory schemes.

How Researchers Evaluate Supplier Quality

Because CJC-1295 has no pharmacopeial monograph and no approved manufacturing pathway, the burden of quality verification sits entirely with the buyer. Documentation is the only real signal, and it should be batch-specific rather than generic.

• Third-party COA per batch. A certificate of analysis from an independent laboratory, tied to the lot number printed on the vial, not a representative document reused across production runs.
• HPLC purity. Reverse-phase HPLC chromatograms establish the percentage of the target peptide relative to synthesis-related impurities, deletion sequences, and degradation products. The chromatogram itself is more informative than a single headline percentage.
• Mass spectrometry identity. MS confirmation that the observed molecular mass matches the theoretical mass for the specific variant — DAC and no-DAC differ substantially, and MS is where mislabeling between them surfaces.
• Batch traceability. A lot number that connects vial, COA, and production run, allowing a laboratory to reconcile anomalous results against a specific batch.
• Presentation consistency. Intact vacuum seal, uniform lyophilized cake, correct labeling, and appropriate cold-chain handling in transit.

Peptide identity, purity, and net peptide content are three separate questions. A COA reporting high HPLC purity says nothing about how much of the vial's mass is peptide versus residual salts and water — which is why laboratories doing quantitative work look for peptide content data where it is available.

Where the Open Questions Are

The honest summary is that CJC-1295 has a well-characterized mechanism and a thin outcomes literature. The receptor pharmacology is clear. The pharmacokinetic contrast between the DAC and no-DAC forms is well described. What is not established is what sustained, long-term upstream stimulation of the GH/IGF-1 axis actually produces over months or years in intact organisms — including whether receptor desensitization emerges, how IGF-1 feedback reshapes the response over time, and what the long-term metabolic consequences of chronically elevated IGF-1 might be.

Other gaps are conspicuous. Human data in older adults, in individuals with metabolic dysfunction, and in females specifically remain limited. Comparative work against other GHRH analogs such as sermorelin and tesamorelin, or against GH secretagogue receptor agonists, is largely absent for this compound. And the frequently discussed effects on sleep, recovery, and body composition have not been isolated in controlled CJC-1295 trials. For researchers designing work in this space, those gaps are the interesting part — and they are the reason careful, well-documented laboratory work still has something to add.

Research-grade CJC-1295: Real Peptides supplies CJC-1295 for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore CJC-1295 research on Real Peptides

The articles below go deeper on the questions researchers ask most about CJC-1295.

Research questions

• Does CJC-1295 Increase Heart Rate? A Clear-Eyed Look
• Does CJC-1295 Spike Blood Pressure? Our Expert Analysis
• CJC-1295 and Hunger: What Our Research Team Has Uncovered
• CJC-1295 & Fatigue: Why This Peptide Can Make You Feel Tired
• CJC 1295 and Libido: The Connection Researchers Are Exploring

Reconstitution, storage & handling

• CJC-1295 No DAC Reconstituted Cloudy Still Good? (Answered)
• CJC-1295 Left Out Fridge Ruined? Temperature Damage
• Does CJC-1295 No DAC Need Refrigeration? (Storage)

Research timelines & mechanisms

• How Long Does CJC-1295 Stay In Your System? A Deep Dive
• The History of CJC-1295: How Long Has It Actually Been Around?

Legal & regulatory

• Why Is CJC 1295 Banned? The Real Story Behind the Restrictions
• Is CJC-1295 No DAC Legal to Purchase for Research?

Safety & side effects

• CJC-1295 Air Bubbles in Syringe: Are They Dangerous?
• Is CJC-1295 Safe According to Studies? (Research Review)
• CJC-1295 No DAC Safety Profile — Research & Risk Data

Stacks & comparisons

• CJC-1295 Real vs Fake: How to Tell — Real Peptides
• CJC-1295 vs. No DAC: Decoding Growth Hormone Peptides

Buying & quality

• CJC-1295 Myths Cost Money Health — Real Peptides

Ordering CJC-1295 for research

Real Peptides supplies CJC-1295 as a research-use-only reference material: lyophilized powder in a sealed vial, labeled with the lot number that matches its published certificate of analysis. Every batch is tested by an independent laboratory before it ships, and the certificate is published before purchase, so a researcher can read the purity result for the exact lot they are ordering.

• Product page: CJC-1295 for research, with the vial formats currently stocked and the certificate for the batch shipping now.
• Certificates: search any lot number at the certificate lookup; reports stay on file after a batch sells out.
• Shipping: orders dispatch within 24 hours on business days from inventory in Florida and California to every US state; see research peptides by location.
• Related compounds: browse the full research peptide catalog.

Nothing on this page is medical advice or guidance on administering any compound. CJC-1295 is not for human or animal use, and buyers confirm they are 21 or older and purchasing for laboratory research.

How does the DAC component extend CJC-1295's duration of action?

The drug affinity complex (DAC) is a maleimidopropionyl group appended to the modified GHRH(1–29) backbone. In plasma, that maleimide reacts covalently with the free thiol on cysteine-34 of circulating albumin, tethering the peptide to a carrier protein with a multi-day turnover. Because the conjugate is too large for rapid renal filtration and is partially shielded from dipeptidyl peptidase-IV cleavage, the apparent elimination profile shifts from minutes to days. Four amino acid substitutions in the parent sequence (D-Ala, Gln, Ala, Leu) further resist enzymatic breakdown at the N-terminus, which is the primary degradation site for native GHRH. The practical consequence studied in the literature is a persistent, low-amplitude GHRH-receptor stimulus rather than a sharp transient one, which is why the compound is frequently described as a GHRH analog with DAC. Teichman and colleagues reported prolonged elevations of growth hormone and IGF-I in healthy adults following single administrations of this albumin-binding analog (PubMed 16352683 (PubMed PMID 16352683)). Researchers comparing pharmacokinetic assumptions often review the half-life literature, the discussion of extended half-life and GH release, and the rationale behind models of sustained GH elevation before designing sampling schedules.

What distinguishes CJC-1295 with DAC from modified GRF 1-29 in laboratory work?

The two compounds share the same 29-amino-acid GHRH fragment with identical stabilizing substitutions; the only structural difference is the DAC linker. Without DAC, the tetrasubstituted analog (often catalogued as modified GRF 1-29 or "CJC-1295 no-DAC") circulates freely and clears on a timescale of roughly half an hour, producing a brief receptor stimulus that approximates an endogenous GHRH pulse. With DAC, albumin conjugation stretches exposure across days and produces a plateau-like signal. Neither version alters receptor identity: both act at the pituitary GHRH receptor, a class B G-protein-coupled receptor coupled to Gs, adenylyl cyclase, and cAMP-dependent transcription of the GH1 gene, as outlined in material on the extended GHRH receptor mechanism. The design question in published preclinical work is therefore whether pulsatile or continuous receptor occupancy is the relevant variable for a given endpoint, since somatotroph responsiveness and hepatic IGF-I output behave differently under each. Laboratories mapping these distinctions typically consult side-by-side peptide comparison material, summaries of the GH release timeline, and overviews of alternative GH-axis research compounds when selecting which variant fits the question being asked.

How is CJC-1295 purity verified by HPLC and mass spectrometry?

Identity and purity assessment for a synthetic 30-residue peptide rests on two complementary techniques. Reversed-phase HPLC, usually on a C18 column with a water/acetonitrile gradient containing trifluoroacetic acid, separates the target peak from truncated sequences, deletion products, and residual synthesis reagents; the chromatogram's area-percent figure is what vendors report as purity. Mass spectrometry — typically ESI-MS or MALDI-TOF — confirms that the observed molecular mass matches the theoretical value for the DAC-modified sequence, distinguishing the correct product from closely eluting impurities that HPLC alone cannot resolve. A credible certificate of analysis pairs both traces with the lot number, test date, and the instrument method, rather than presenting a bare percentage. Secondary data sometimes included are water content by Karl Fischer titration, acetate counter-ion content, and peptide content by amino acid analysis, which explains why net peptide mass can differ from vial fill mass. Laboratories reviewing documentation often cross-reference a buying guide for researchers, background on degradation in reconstituted material, and bioavailability research considerations. Common documentation questions are also collected in the compound FAQ.

Why do study designs combine CJC-1295 with a ghrelin-receptor agonist?

The GH axis has two independent stimulatory inputs. GHRH analogs act on the GHRH receptor to raise cAMP and promote GH transcription and release; growth hormone secretagogues such as ipamorelin act on the GHS-R1a (ghrelin) receptor through a Gq/phospholipase C pathway that mobilizes intracellular calcium, and they also blunt somatostatin tone. Because the two receptors converge on the same somatotroph through different second messengers, co-stimulation in experimental models produces a larger GH signal than either input alone — the classic rationale for pairing them in research. Selectivity is part of the appeal: ipamorelin was characterized as a secretagogue with minimal effect on cortisol and prolactin in the original pharmacology work, which simplifies interpretation of downstream endpoints. Investigators evaluating this pairing generally review the combined mechanism of action, the reasoning behind describing it as a standard GH-axis research pairing, and comparative material on related research peptides. Experimental timing variables — continuous versus intermittent exposure, and how long a model is observed — are discussed in literature on combination research design. Negative-feedback from rising IGF-I remains a confounder in any extended design.

Which biomarkers do researchers measure in CJC-1295 experiments?

Serum growth hormone is the proximal readout, but its pulsatile nature makes single time-point sampling unreliable; frequent sampling, area-under-the-curve calculation, or deconvolution analysis is standard in GH-axis pharmacology. IGF-I is the more stable integrative marker, since hepatic IGF-I production responds to cumulative GH exposure over roughly 24–72 hours and varies far less minute to minute. IGFBP-3 and the acid-labile subunit are often measured alongside IGF-I because they form the ternary complex that determines IGF-I's circulating lifespan. Secondary endpoints reported in GH-axis research include fasting glucose and insulin, since GH is counter-regulatory to insulin, and occasionally prolactin and cortisol to confirm pituitary selectivity. The clinical study of this albumin-binding GHRH analog in healthy adults measured both GH and IGF-I responses after single administrations (PubMed 16352683 (PubMed PMID 16352683)). Assay choice matters: immunoassay and LC-MS/MS platforms for IGF-I are not interchangeable without harmonization. Overviews of laboratory markers tracked in this research area, background on GH release as an endpoint, notes on current clinical trial activity, and in vitro cell-model work help frame endpoint selection.

What do animal models show that human clinical data on CJC-1295 do not?

Animal work allows tissue-level sampling that human studies cannot provide: pituitary somatotroph morphology, hepatic IGF-I mRNA expression, GHRH receptor density after prolonged stimulation, and bone or muscle histology at defined time points. Rodent and larger-animal GHRH-analog studies have also been used to probe whether continuous receptor occupancy causes somatotroph desensitization or depletion — a question that cannot be resolved from circulating hormone data alone. Human data, by contrast, are limited mostly to short pharmacokinetic and pharmacodynamic studies in healthy volunteers, which characterize the GH and IGF-I response profile but say little about chronic tissue adaptation. Species differences complicate translation: GHRH receptor sequence homology is high but not identical, albumin cysteine-34 availability differs, and baseline GH pulsatility patterns in rodents differ markedly from primates. Reviews comparing animal research mechanisms and findings with the direct animal versus human research comparison make these limits explicit. The development history of the compound explains why much of the preclinical record predates the small clinical dataset, and orientation material such as a beginner's overview summarizes where the evidence base currently stops.

What does the literature report about body-composition endpoints in GHRH-analog research?

Growth hormone and IGF-I influence body composition through several well-described pathways: GH promotes hormone-sensitive lipase activity and lipolysis in adipose tissue, suppresses lipoprotein lipase-mediated fatty acid uptake, and shifts substrate use toward fat oxidation, while IGF-I supports nitrogen retention and satellite-cell activity in skeletal muscle. In GH-deficient models, replacing the GH signal reliably changes fat mass and lean mass measures. Whether a GHRH analog that raises GH modestly in an intact axis produces comparable changes is a separate and much less settled question, because negative feedback from IGF-I and somatostatin constrains how far the axis can be pushed. Published work on this specific compound is weighted toward pharmacokinetics and hormone output rather than long-term composition endpoints, so claims about physique outcomes outrun the dataset. Researchers examining these endpoints commonly review body recomposition study design, background on fat metabolism pathways, the evidence summary for fat-loss mechanisms, and material on muscle growth endpoints. DEXA, MRI-based adipose quantification, and nitrogen balance are the measurement standards; bodyweight alone is considered an inadequate proxy in this literature.

How does CJC-1295 relate to sleep and recovery endpoints in research?

The link between the GH axis and sleep is bidirectional and well established in neuroendocrinology. The largest spontaneous GH pulse in humans occurs shortly after sleep onset and coincides with slow-wave sleep, and hypothalamic GHRH neurons are themselves implicated in promoting non-REM sleep independently of their pituitary action — central GHRH administration increases slow-wave activity in animal models, while GHRH antagonism reduces it. That makes GHRH receptor signaling a plausible mechanistic bridge between the compound class and sleep-architecture endpoints measured by polysomnography: slow-wave sleep duration, delta power, and sleep-onset latency. Direct published evidence for this specific albumin-bound analog on sleep variables is sparse, and the distinction between a pituitary effect and a central hypothalamic effect matters, since an albumin-conjugated peptide is not expected to cross the blood-brain barrier readily. Recovery endpoints in the broader GH literature focus on collagen synthesis markers, tendon and connective-tissue turnover, and nitrogen balance rather than subjective measures. Research summaries covering sleep-related endpoints, the mechanistic and clinical sleep data, recovery-focused study questions, and age-related GH-axis research outline where measurable evidence exists and where it remains inferential.

What tolerability and safety signals appear in the CJC-1295 literature?

Reported observations in GHRH-analog studies fall into predictable mechanistic categories. Transient local reactions and flushing are described for GHRH-class peptides generally. Metabolically, sustained GH elevation is counter-regulatory to insulin and can raise fasting glucose and reduce insulin sensitivity, which is why glucose handling appears as a monitored variable in GH-axis trials. Fluid retention, joint discomfort, and paresthesia are classic GH-excess findings documented across the broader GH replacement literature and are therefore plausible class effects at high exposure. A theoretical concern raised for any agent that chronically elevates IGF-I is mitogenic signaling, though no causal data exist for this compound and the question remains unresolved. The clinical dataset itself is small: the published healthy-adult pharmacology study of this analog was short in duration and limited in participant numbers (PubMed 16352683 (PubMed PMID 16352683)), so long-horizon safety characterization is absent. Researchers reviewing this ground typically consult the side-effect evidence review, documented contraindication considerations, notes on interactions with other compounds, and the balancing summary of reported benefits in the literature. All such material describes laboratory findings only; the compound is not approved for human use.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286